Lexaria Bioscience LEXX
NASDAQ LEXX
$3.04 -0.05 (-1.62%)
As of: Oct 2, 2026 · 12:02 PM EDT

Lexaria Bioscience (LEXX) Accumulated Expenses (2019 - 2022)

Updated

Lexaria Bioscience (LEXX) reported Accumulated Expenses of $6,884 for fiscal Q2 2022 (quarter ended Feb 28, 2022).

Analysis

Lexaria Bioscience (LEXX) Accumulated Expenses (2019 - 2022) Analysis & Trends

  • The fiscal Q2 2022 figure ranks as the highest quarterly Accumulated Expenses since fiscal Q2 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Lexaria Bioscience 3.26 Mn -12.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Feb 28, 2022 6,884.00
Feb 28, 2019 334,523.00
API Access

Lexaria Bioscience Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=LEXX&period=max&api_key=YOUR_API_KEY